Avacta’s flagship will soon begin Phase 1b clinical trials. Measuring its chances of success is harder than it looks.
I have been covering Avacta’s growth story for some time now.
For the duration, I have characterised the biotech firm as extremely high-risk, high-reward — and have tried to make this opinion clear, whether for UK Investor Magazine, IG Index, or elsewhere.
In my view, the company’s success hinges on whether AVA6000 is successful as this would prove the efficacy of the entire pre|CISION pipeline.
But estimating the chance of success is easier said than done — with...
